| Bioactivity | Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2]. |
| Invitro | Keliximab 与可溶性 CD4 结合的 Kd 值为 1.0 nM[2]。Keliximab (0.01-10 μg/mL；30 分钟) 剂量依赖性地结合 CD4+ 胸腺瘤细胞系 SupT1，ED50 为 0.2 μg/mL[1]。Keliximab (0-1000ng/mL) 在原发性人浆母细胞淋巴瘤 (PBLs) 中阻断 T 细胞增殖和 IL-2 产生，IC50 为 10-30 ng/mL[1]。Keliximab (1-1000 ng/mL；5 分钟) 剂量依赖性地介导细胞粘附，ED50 为 20 ng/mL[1]。 |
| In Vivo | Keliximab (5-125 mg/kg；静脉注射，1 次) 减少 CD4+ T 细胞[1]。 Animal Model: |
| Name | Keliximab |
| CAS | 174722-30-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. [2]. Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84. |